Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 27-04-2018

Legal Publication Date:- 23-05-2018

Journal Code (180523)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

23-04-2018		
273/2018	Dr. Gul-e-Rana **PCSIR** Karachi – Pakistan	"Development of Method for preparation of Permanent Black Ink from Pakistani Lignite Coal Char"
274/2018	UCB BIOPHARMA SPRL Belgium SANOFI France (Priority 25-04-2017 EP)	"FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY"
275/2018	Syngenta Participations AG Switzerland (Priority 25-04-2017 IN)	"Pesticidally active heterocyclic derivatives with sulfur containing substituents"
24-04-2018		
276/2018	Kite Pharma Inc., USA (Priority 24-04-2017 US)	"HUMANIZED ANTIGEN-BINDING DOMAINS AND METHODS OF USE"
277/2018	Novartis AG Switzerland ADURO Biotech, Inc., USA (Priority 28-04-2017 US)	"BIS 2'-5'RR-(3'F-A)(3'F-A)CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF"
25-04-2018		

278/2018	ISHIHARA SANGYO KAISHA, LTD., **Japan** (Priority 27-04-2017 JP)	"N-(4-PYRIDYL)NICOTINAMIDE COMPOUND OR SALT THEREOF"
279/2018	Novartis AG Switzerland (Priority 27-04-2017 US)	"FUSED INDAZOLE PYRIDONE COMPOUNDS AS ANTIVIRALS"
280/2018	Sumitomo SHI FW Energia Oy Finland (Priority 28-04-2017 EP)	"A FLUIDIZING GAS NOZZLE HEAD AND A FLUIDIZED BED REACTOR WITH MULTIPLE FLUIDIZING GAS NOZZLE HEADS"
26-04-2018		
281/2018	Khurram Saleem Joya Noor-Ul-Ain Babar M. Arsalan Lahore – Pakistan	"COLLOIDAL SYNTHESIS OF THIN-FILM METAL OXIDES/HYDROXIDES NANOELECTROCATALYSTS FOR WATER SPLITTING, FUEL GENERATION, AND FOR ENERGY CONVERSION APPLICATION"
282/2018	FOO YONG MALAYSIA (Priority 27-04-2017 MALAYSIA)	"SYSTEM AND METHOD FOR DETERMINING DAILY PROFIT AND LOSS TO IMPROVE THE EFFICIENCY OF DAY TO DAY BUSINESS OPERATIONAL ACTIVITIES"
283/2018	British American Tobacco (Investments) Limited United Kingdom (Priority 28-04-2017 UK)	"METHOD"
284/2018	Novartis AG Switzerland	"ANT1BODY CONJUGATES COMPRISING TOLL-LIKE

	(Priority 28-04-2017 US)	RECEPTOR AGONIST AND COMBINATION THERAPIES"
285/2018	Novartis AG Switzerland (Priority 28-04-2017 US)	"6-6 Fused Bicyclic Heteroaryl Compounds and their Uses as LATS Inhibitors"
27-04-2018		
286/2018	FMC Corporation USA (Priority 02-05-2017 US)	"PYRIMIDINYLOXY BENZO-FUSED COMPOUNDS AS HERBICIDES"
287/2018	BAYER AKTIENGESELLSCHAFT Germany (Priority 02-05-2017 EP)	"2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES"
288/2018	BAYER AKTIENGESELLSCHAFT Germany (Priority 02-05-2017 EP)	"2-(HET)ARYL-SUBSTITUTED FUSED HETEROCYCLE DERIVATIVES AS PESTICIDES"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

918/2007	Novartis AG Switzerland	"SUBSTITUTED CYCLOHEXYL-PYRROLIDIN-1-YL}-2-OXO-ETHYL)-2-METHYLAMINO-PROPIONAMIDE COMPOUND" C07K5/06, A61P35/00 , A61K31/427 & A61K31/4439. **142789** The present invention is directed to a compound of the formula:  Specifically, disclosed is a compound which is selected from (S)-N-((S)-1-Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide or (S)-N-((S)-1 -Cyclohexyl-2-{(S)-2-[5-(4-fluoro-benzoyl)-pyridin-3-yl]-pyrrolidin-1 -yl}-2-oxo-

		ethyl)–2-methylamino-propionamide, and a pharmaceutical composition comprising thereof for treating proliferative diseases such as cancer, in mammals.
1365/ 2007	Merck Sharp & Dohme Corp. U.S.A.	"SUBSTITUTED DIAZEPAN COMPOUND" C07D401/14 & C07D213/00. **142790** The present invention is directed to a compound 5-chloro-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl] -1 ,4-diazepan-1-yl } -1,3 -benzoxazole which is antagonist of orexin receptor, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention further provides a pharmaceutical composition comprising above compound and a pharmaceutically acceptable carrier.
1171/2008	Cilag AG, Switzerland	"Method of producing 2'-deoxy-5-azacytidine (Decitabine)" C07H19/12. **142791** Method of producing 2'-deoxy-5-azacytidine (Decitabine) by providing a compound of formula (I):  wherein R is a removable substituent known per Se; and R1 is a removable substituent; further providing a silylated base of formula (II): 

		wherein R2 is a protecting group, preferably a trimethylsilyl TMS)-residue; reacting the compound of formula (I) and the compound of formula (II) together in a suitable anhydrous solvent and in the presence of a suitable catalyst; and removing the substituents R from the compound obtained in order to obtain the compound 2' -deoxy-5-azacytidine (Decitabine), characterized in that said catalyst is selected from the group comprising a salt of an aliphatic sulphonic acid or a salt of a strong inorganic acid.
1390/ 2008	NOVARTIS AG Switzerland	"PHARMACEUTICALLY ACCEPTABLE SALT OF SUBSTITUTED CYCLOHEXYL-PYRROLIDIN-1 -YL}-2-OXO-ETHYL)-2-METHYLAMINO-PROPIONAMIDE COMPOUND" C09K5/06,A61P35/00, A61K31/4439 & A61K31/427. **142792** The present invention is directed to a pharmaceutically acceptable salt of a compound of the formula:  Specifically, disclosed is a pharmaceutically acceptable salt of a compound which is selected from (S)-N-((S)-1 -Cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1 -yl}-2-oxo¬ethyl)-2-methylamino-propionamide or (S)-N-((S)-1 -Cyclohexyl-2-{(S)-2-[5-(4-fluoro-benzoyl)¬pyridin-3-yl]-pyrrolidin- 1 -yl}-2-oxo-ethyl)-2-methylamino-propionamide, and a pharmaceutical composition comprising thereof for treating proliferative diseases such as cancer, in mammals.

1443/ 2008	Novartis AG Switzerland	"SUBSTITUTED AMINOTHIAZOLE COMPOUND" A61P31/00 , C07D417/04 & A61K31/427. **142793** The present application describes a compound of formula:  that is useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections.
350/ 2009	NOVARTIS AG Switzerland	" SUBSTITUTED 2,3,4,9-TETRAHYDROSPIRO ß-CARBOLINE-1,3'-INDOLONE COMPOUND" A61K31/407, A61K31/424 & A61P33/06. **142794** The invention relates to a compound of formula I

		 (I) wherein m, R^1, R^2, R^3, R^4, R^5, n, A and B have meaning as defined in the specification. The compound has interesting pharmaceutical properties, in particular, the compound is useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example, Leishmania donovani. The invention also relates to pharmaceutical compositions containing the compound, as well as processes for its preparation.
732/ 2009	NOVARTIS AG Switzerland	"SUBSTITUTED PHENYLAMINOMETHYL-CYCLOHEXYL-BENZAMIDE COMPOUND" C07C233/00,C07K14/695 & A61K38/25. **142795** There is described a compound of formula I  where R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{17} and R^{22} are as herein defined as corticotropin

		releasing factor (CRF_1) receptor antagonist.
36/ 2011	Sachtleben Chemie GmbH Germany	"Anatase white pigment with high light and weather resistance" C01G23/053 & C09C1/36. **142796** The invention concerns to an anatase white pigment which is doped in compensatory mode with a trivalent cation selected from Al, Ga, In and Ce, and a further cation selected from the group consisting of a monovalent cation selected from Li, Na and K and a pentavalent cation selected from Sb and Nb, wherein the further cation is present in an amount of less than 1.5 mol% with respect to Ti in the base substanceTiO2 pigments in the anatase modification with increased light and weather resistance, wherein the TiO2 pigments have advantages in respect of blue tint, low hardness and abrasiveness.
50/ 2011	Glaxo Group Limited United Kingdom	"Antigen binding protein specifically binding to CD127" C07K16/28. **142797** The present invention relates to antigen binding protein which specifically binds to CD127 and can be used in therapeutic methods, in particular, in the treatment or prevention of diseases in which pathogenic TH17 cells are implicated. It specifically relates to an anti-CD127 antibody comprising a heavy chain variable region having a sequence selected from the group consisting of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 17, 121, 123, 125, 127, 129 and 131.
384/ 2011	Unilever PLC. United Kingdom	"A PROCESS OF PREPARATION OF TEA" A23F3/06 & A23F3/10.

		142798 The present invention relates to a process of preparation of tea. It particularly relates to processing of green tea or white tea. Aroma of conventionally processed green or white tea is relatively poor in honey fruity and/or floral character, Green tea is relatively less liked by non-traditional consumers of green tea as the green tea (and instant green tea) has relatively less aroma. The present inventors have surprisingly found that green leaf tea obtained by a process involving a step of anaerobic incubation at specific temperature and for specific duration whilst avoiding certain steps provides end-cup aroma with specific aroma volatile compounds in specific mass ratios and consequently has an aroma with enhanced honey, floral and/or fruity notes and yet retains relatively high amount of catechins.
547/ 2012	Regeneron Pharmaceuticals, Inc. U.S.A.	"ANTI-TIE2 ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF" C07K16/00 & C07K16/18. **142799** The present invention provides antibody that specifically binds human Tie2 (tyrosine kinase receptor) and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The present invention further provides a pharmaceutical composition comprising the said antibody along with pharmaceutical acceptable carrier or diluent. The antibody of the invention is useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.
735/ 2012	Akzo Nobel Coatings International B.V.	"A ONE PACK AQUEOUS INSECTICAL ARCHITECTURAL COMPOSITION"

	Netherlands	**142800** A one pack aqueous insecticidal architectural coating composition comprising an aqueous dispersion of polymer particles as binder and further comprising, based on the total liquid paint formulation, i) from 0.1 to 4.0wt% insecticide ii) from 0.5 to 6.5wt% dibasic ester solvent wherein the insecticide is located in the polymer particles and the polymer particles are film forming at ambient temperatures.
108/ 2013	BOEHRINGER INGELHEIM INTERNATIONAL GmbH Germany	"CX3CR1-BINDING POLYPEPTIDE" C07K16/28. **142801** The present invention relates to CX3CR1-binding polypeptide, in particular polypeptide comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptide; to method for preparing such polypeptide; to host cell expressing or capable of expressing such polypeptide; to composition comprising such polypeptide; and to use of such polypeptide or such composition, in particular for prophylactic, therapeutic and diagnostic purposes.
387/ 2013	NOVARTIS AG Switzerland	"PHARMACEUTICALLY ACCEPTABLE SALT OF A SUBSTITUTED PHENYLAMINOMETHYL-CYCLOHEXYL-BENZAMIDE COMPOUND" A61P1/00,A61K31/166, A61K31/427 & A61K31/44. **142802** There is described a pharmaceutically acceptable salt of a compound of formula Xl

		 wherein R^7, R^8, R^{18}, R^{19} and R^{20} are as herein defined as corticotropin releasing factor (CRF_1) receptor antagonist.
852/ 2013	HANMI PHARM. CO., LTD. Republic of Korea.	"AN AMORPHOUS SOLID DISPERSION WITH IMPROVED SOLUBILITY COMPRISING TETRAZOLE COMPOUND" A61K31/41, C07D257/04 & A61K31/4725. **142803** The present invention relates to an amorphous solid dispersion comprising a tetrazole derivative of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The solid dispersion of the present invention comprises a water-soluble polymer or an acid so as to improve the solubility of its active ingredient, i.e., the tetrazole derivative of the formula (I), thereby improving its absorption rate, and thus can be effectively used to reduce multi-drug resistance (MDR) in cancer cells.
689/ 2015	ELI LILLY AND COMPANY U.S.A.	"(2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6- [(5-methyl-1H-pyrazol-3-yl)amino] -2-pyridyl] methyl]-2-methyl-piperidine-4-carboxylic acid compound" C07D401/14, A61K31/4545 & A61P35/00. **142804** The present invention provides an aminopyridine compound, that inhibits Aurora A and, therefore may be useful in treating cancer.

SEALING FEES DUE-

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of **Rs.4500/-** should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

Accepted No.	Applicant Name	Application No.
142651	BP Corporation North America Inc., USA.	428/2006
142652	Dr. Mohammad A. Khan Mr. Mohammad Arif Dr. Imtiaz-ud-Din Dr. Khalid Mohammad Khan Dr. Nida Ambreen Dr.Shahnaz Perveen Pakistan.	113/2012
142653	CHIESI FARMACEUTICI S.P.A., Italy.	161/2012
142654	Engr. Muhammad Ashraf Farid Ahmed Yasin Syed Faisal Imam Khalid Saleem Khan Ali Sultan Pakistan.	326/2012
142655	AMERICAN PACIFIC CORPORATION USA	676/2012
142656	Phenex Pharmaceuticals AG, Germany	340/2013
142657	F. HOFFMANN-LA ROCHE AG Switzerland	475/2015
142658	F. HOFFMANN-LA ROCHE AG Switzerland	683/2016

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
23/04/2018			
1.	19304	Tweezer (Class 01)	Waqas Hussain, Trading as M/s. Stylish Beauty Industry
2.	19305	Tweezer (Class 01)	Waqas Hussain, Trading as M/s. Stylish Beauty Industry
24/04/2018			
3.	19306	Nail Polish Bottle (Class-04)	Farhan Aftab trading as Aftab & Sons
25/04/2018			
4.	19307	T-Shirt (Class 13)	Syed Yasir Abbas trading as Powerway's
5.	19308	T-Shirt (Class 13)	Syed Yasir Abbas trading as Powerway's
26/04/2018			
6.	19309	United Panjnad (Class 03)	Sana Ullah Chaudhry (Managing Director)
7.	19310	United Panjnad (Class 01)	Sana Ullah Chaudhry (Managing Director)

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
26/04/2018			
1.	17329	Mobile Phone (Class-03)	Digicom Trading (Pvt.) Limited
2.	17330	Mobile Phone (Class-03)	Digicom Trading (Pvt.) Limited
3.	18891	Mobile Phone (Class-3)	Digicom Trading (Pvt.) Limited
4.	18892	Mobile Phone (Class-3)	Digicom Trading (Pvt.) Limited
27/04/2018			
5.	19111	PLASTIC PALLET (Class-12)	ARCO Plastics
6.	19112	PLASTIC PALLET (Class-12)	ARCO Plastics
7.	19113	PLASTIC PALLET (Class-12)	ARCO Plastics
8.	19114	PLASTIC PALLET (Class-12)	ARCO Plastics
9.	19115	PLASTIC PALLET (Class-12)	ARCO Plastics

(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591